Literature DB >> 8366471

Migraine and depression: biological aspects.

V Glover1, J Jarman, M Sandler.   

Abstract

There is a considerable overlap in migraine and depression incidence, and both conditions may be associated with low levels of 5-hydroxytryptamine (5-HT). During a migraine attack there is evidence for low levels of platelet 5-HT and possibly also low Vmax for 5-HT uptake; both these findings are also associated with the depressed state. Both conditions can be treated by tricyclic and monoamine oxidase inhibiting antidepressants. However, there are also clear differences: migraine attacks are brief and self limiting. Part of the migraine cascade occurs outside the blood brain barrier, presumably involving blood vessels and, unlike depression, migraine attacks can be ameliorated by drugs which only act peripherally. In addition, migraine patients, especially males, often have permanently low levels of platelet monoamine oxidase activity, whereas patients with unipolar depression tend to have raised levels of this marker. This low enzyme activity may reflect part of the vulnerability to migraine, often associated in the prodromal phase with agitation or hyperactivity. Migraine may form part of a family of brief recurrent self-limiting disorders, which involve disturbances of both mood and monoamines; during the headache phase of the attack, the links with depression are most apparent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8366471     DOI: 10.1016/0022-3956(93)90010-y

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  9 in total

Review 1.  Psychiatric comorbidity in chronic daily headache: pathophysiology, etiology, and diagnosis.

Authors:  Vincenzo Guidetti; Federica Galli
Journal:  Curr Pain Headache Rep       Date:  2002-12

2.  Microtrial methods for translating gene-environment dynamics into preventive interventions.

Authors:  George W Howe; Steven R H Beach; Gene H Brody
Journal:  Prev Sci       Date:  2010-12

3.  [Substance P, somatostatin and monoaminergic transmitters in the cerebrospinal fluid of patients with chronic idiopathic trigeminal neuralgia].

Authors:  M Strittmatter; M Grauer; E Isenberg; G Hamann; C Fischer; K H Hoffmann; F Blaes; K Schimrigk
Journal:  Schmerz       Date:  1996-10-28       Impact factor: 1.107

4.  The relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies.

Authors:  Robert A Philibert; Harinder Sandhu; Nancy Hollenbeck; Tracy Gunter; William Adams; Anup Madan
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-07-05       Impact factor: 3.568

5.  Locus of control moderates the relationship between headache pain and depression.

Authors:  Robin L Heath; Matilda Saliba; Oula Mahmassani; Stella C Major; Brigitte A Khoury
Journal:  J Headache Pain       Date:  2008-08-05       Impact factor: 7.277

6.  Methylation at SLC6A4 is linked to family history of child abuse: an examination of the Iowa Adoptee sample.

Authors:  Steven R H Beach; Gene H Brody; Alexandre A Todorov; Tracy D Gunter; Robert A Philibert
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

7.  Phospholipase C activity increases in cerebrospinal fluid from migraineurs in proportion to the number of comorbid conditions: a case-control study.

Authors:  Alfred N Fonteh; Janice M Pogoda; Rainbow Chung; Robert P Cowan; Michael G Harrington
Journal:  J Headache Pain       Date:  2013-07-04       Impact factor: 7.277

8.  Impact of UVA exposure on psychological parameters and circulating serotonin and melatonin.

Authors:  Thilo Gambichler; Armin Bader; Mirjana Vojvodic; Falk G Bechara; Kirsten Sauermann; Peter Altmeyer; Klaus Hoffmann
Journal:  BMC Dermatol       Date:  2002-04-12

Review 9.  Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology.

Authors:  Andrea I Loewendorf; Anna Matynia; Hakob Saribekyan; Noah Gross; Marie Csete; Mike Harrington
Journal:  Front Immunol       Date:  2016-04-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.